The use of myo-inositol in the treatment of female infertility in assisted reproductive technology programs in patients at high risk for immature gametes
Objective. To analyze the data available in the current literature on the effect of myo-inositol on the effectiveness of assisted reproductive technology (ART) programs and its role in the physiology of the female reproductive system.Vladimirova I.V., Donnikov A.E., Makarova N.P., Kalinina E.A.
Material and methods. The article includes the data of foreign and Russian articles published in the past 5 years and found in Pubmed on this topic.
Results. Possible mechanisms of myo-inositol involvement in oocyte maturation processes are described. The use of myo-inositol in the treatment of infertility in patients at high risk for obtaining immature germ cells (oocytes) can improve the quality of oocytes obtained during superovulation and increase the frequency of fertilization at the embryonic stage.
Conclusion. In detecting a high risk of obtaining immature sex cells, the use of myo-inositol in IVF preparation programs can increase the chance of obtaining mature oocytes by providing a full meiotic, as well as reduce the hormonal load and increase the effectiveness of the procedure in general.
Keywords
gene polymorphism
molecular genetic predictors
myo-inositol
immature oocytes
infertility
in vitro fertilization (IVF)
References
1. Pacchiarotti A., Selman H., Valeri C., Napoletano S., Sbracia M., Antonini G. et al. Ovarian stimulation protocol in IVF: An up-to-date review of the literature. Curr. Pharm. Biotechnol. 2016; 17(4): 303-15.
2. Vladimirova I.V., Kalinina E.A., Donnikov A.E. A model for predicting the probability of obtaining immature oocytes in assisted reproductive technology programs with regard to the genotype of patients. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016; (1): 63-67. (in Russian) http://dx.doi.org/10.18565/aig.2016.1.63-67
3. Rago R., Marcucci I., Leto G., Caponecchia L., Salacone P., Bonanni P. et al. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J. Biol. Regul. Homeost. Agents. 2015; 29(4): 913-23.
4. Vladimirova I.V., Kalinina E.A., Donnikov A.E. Predicting the outcomes of programs of assisted reproductive technologies using molecular genetic markers. Ginekologiya. 2014; 16 (6): 33-6. (in Russian)
5. Gromova O.A., Torshin I.Yu., Grishina T.R., Gromov A.N., Limanova O.A. A systematic analysis of the molecular-physiological effects of myoinositol: data from molecular biology, experimental and clinical medicine. Effektivnaya farmakoterapiya. 2013; 23: 4-12. (in Russian)
6. Venturella R., Mocciaro R., De Trana E., D’Alessandro P., Morelli M., Zullo F. Assessment of the modification of the clinical, endocrinal and metabolical profile of patients with PCOS syndrome treated with myo-inositol. Minerva Ginecol. 2012; 64(3): 239-43.
7. Turan G.A., Eskicioglu F., Sivrikoz O.N., Cengiz H., Adakan S., Gur E.B. et al. Erratum to: Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study. Arch. Gynecol. Obstet. 2016; 293(3): 691.
8. Lisi F., Carfagna P., Oliva M.M., Rago R., Lisi R., Poverini R. et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod. Biol. Endocrinol. 2012; 10: 52.
9. Konieczny V., Stefanakis J.G., Sitsanidis E.D., Ioannidou N.A., Papadopoulos N.V., Fylaktakidou K.C. et al. Synthesis of inositol phosphate-based competitive antagonists of inositol 1,4,5-trisphosphate receptors. Org. Biomol. Chem. 2016; 14(8): 2504-14.
Received 28.08.2016
Accepted 02.09.2016
About the Authors
Vladimirova I.V., researcher of the Department of assistive reproductive technology in the treatment of infertility, Research Center of Obstetrics,Gynecology, and Perinatology. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74955314444, ext. 2120. E-mail: inteterina@yandex.ru
Donnikov A.E., PhD, senior researcher of laboratory of molecular genetic methods, Research Center of Obstetrics, Gynecology, and Perinatology.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381341. E-mail: a_donnikov@oparina4.ru
Makarova N.P., M.D., Ph.D., Head of the Department of assistive reproductive technology in the treatment of infertility, Research Center of Obstetrics,
Gynecology, and Perinatology. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74955314444, ext. 2120. E-mail: np_makarova@oparina4.ru
Kalinina E.A., M.D., Ph.D., Head of the Department of assistive reproductive technology in the treatment of infertility, Research Center of Obstetrics,
Gynecology, and Perinatology. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74955314444, ext. 2120. E-mail: e_kalinina@oparina4.ru
For citations: Vladimirova I.V., Donnikov A.E., Makarova N.P., Kalinina E.A.
The use of myo-inositol in the treatment of female infertility in assisted reproductive
technology programs in patients at high risk for immature gametes.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (7): 146-9. (in Russian)
http://dx.doi.org/10.18565/aig.2017.7.146-9
Similar Articles
